KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Common Equity (2016 - 2025)

Historic Common Equity for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $18.3 billion.

  • Biogen's Common Equity rose 921.75% to $18.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.3 billion, marking a year-over-year increase of 921.75%. This contributed to the annual value of $18.3 billion for FY2025, which is 921.75% up from last year.
  • Latest data reveals that Biogen reported Common Equity of $18.3 billion as of Q4 2025, which was up 921.75% from $18.2 billion recorded in Q3 2025.
  • Over the past 5 years, Biogen's Common Equity peaked at $18.3 billion during Q4 2025, and registered a low of $10.7 billion during Q1 2021.
  • Over the past 5 years, Biogen's median Common Equity value was $14.5 billion (recorded in 2023), while the average stood at $14.3 billion.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 1494.55% in 2021, then soared by 2287.11% in 2023.
  • Over the past 5 years, Biogen's Common Equity (Quarter) stood at $11.0 billion in 2021, then grew by 22.16% to $13.4 billion in 2022, then grew by 10.54% to $14.8 billion in 2023, then grew by 12.95% to $16.7 billion in 2024, then rose by 9.22% to $18.3 billion in 2025.
  • Its last three reported values are $18.3 billion in Q4 2025, $18.2 billion for Q3 2025, and $17.6 billion during Q2 2025.